Your browser doesn't support javascript.
Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
Pagliusi, Sonia; Jarrett, Stephen; Hayman, Benoit; Kreysa, Ulrike; Prasad, Sai D; Reers, Martin; Hong Thai, Pham; Wu, Ke; Zhang, Youn Tao; Baek, Yeong Ok; Kumar, Anand; Evtushenko, Anatoly; Jadhav, Suresh; Meng, Weining; Dat, Do Tuan; Huang, Weidan; Desai, Samir.
  • Pagliusi S; DCVMN International, Route de Crassier 7, 1262 Eysins-Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn.net.
  • Jarrett S; Gracious International, 28 Jiafeng Road, Shanghai 200131, China. Electronic address: swjarrett@graciousgroup.com.
  • Hayman B; DCVMN International, Switzerland. Electronic address: b.hayman@dcvmn.net.
  • Kreysa U; GS1, Avenue Louise 326, 1050 Bruxelles, Belgium. Electronic address: ulrike.kreysa@gs1.org.
  • Prasad SD; Bharat Biotech, Hyderabad, India. Electronic address: Prasadsd@bharatbiotech.com.
  • Reers M; Biological E Ltd., Hyderabad, India. Electronic address: martin.reers@biologicale.com.
  • Hong Thai P; BioNet-Asia, Bangkok, Thailand. Electronic address: hongthai@bionet-asia.com.
  • Wu K; Bravovax, Wuhan, China. Electronic address: ke.wu@bravovax.com.
  • Zhang YT; China National Biotech Group, Beijing, China. Electronic address: zhangyuntao@sinopharm.com.
  • Baek YO; EuBiologics, Seoul, South Korea. Electronic address: yobaek@eubiologics.com.
  • Kumar A; Indian Immunologicals Ltd., Hyderabad, India. Electronic address: anandkumar@indimmune.com.
  • Evtushenko A; St. Petersburg Research Institute of Vaccines and Serums, Russia. Electronic address: a.e.evtushenko@spbniivs.ru.
  • Jadhav S; Serum Institute of India, Pune, India. Electronic address: ssj@seruminstitute.com.
  • Meng W; Sinovac Biotech, Beijing, China. Electronic address: mengwn@sinovac.com.
  • Dat DT; Vabiotech, Hanoi, Viet Nam. Electronic address: dotuandat@vabiotech.com.vn.
  • Huang W; Innovax Biotech, Xiamen, China. Electronic address: weidan_huang@innovax.cn.
  • Desai S; Zydus Cadila, Ahmedabad, India. Electronic address: samirdesai@zyduscadila.com.
Vaccine ; 38(34): 5418-5423, 2020 07 22.
Article in English | MEDLINE | ID: covidwho-1135582
ABSTRACT
The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Biomedical Research / Drug Industry / Pandemics / International Cooperation Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Biomedical Research / Drug Industry / Pandemics / International Cooperation Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2020 Document Type: Article